Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 9

Medication-related osteonecrosis of the jaw: A survey of knowledge, practices and opinions of dentists

Pages
2421–2427
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For this purpose, training strategies related to MRONJ should be established.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study was to evaluate dentists on their knowledge on biphosphonates, medication related osteonecrosis of the jaw (MRONJ), and on the treatment approaches towards patients using bisphosphonates in the Faculty of Dentistry at İzmir Katip Çelebi University.Material and Methods: This was a questionnaire-based cross-sectional study conducted on 97 dentists.
📊
Key Findings & Data:The surveys consists of a total of 20 questions and four sections, with statistical analysis being used on the collected data.
💡
Conclusion & Impact:For this purpose, training strategies related to MRONJ should be established.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study was to evaluate dentists on their knowledge on biphosphonates, medication related osteonecrosis of the jaw (MRONJ), and on the treatment approaches towards patients using bisphosphonates in the Faculty of Dentistry at İzmir Katip Çelebi University.Material and Methods: This was a questionnaire-based cross-sectional study conducted on 97 dentists. The surveys consists of a total of 20 questions and four sections, with statistical analysis being used on the collected data. The Chi-square and Student-t tests were utilized to compare between the groups. The significance level was set at p 0.05). In the second part of the questionnaire, the dentists were asked various questions in order to measure their general knowledge regarding bisphosphonates and MRONJ. There was no significant difference between the groups in terms of correct answers (p> 0.05). In the third part of the questionnaire, surgical scenarios were presented to the dentists and generally, they preferred the option in which no procedure should be performed in patients who take intravenous (IV) bisphosphonates, regardless of the duration of use.Conclusions: Increasing the awareness of medical practitioners, dentists, and patients in the use and side effects of bisphosphonates is important for preventing MRONJ. For this purpose, training strategies related to MRONJ should be established.

🔖

Cite This Article

SAHİN, O. (2022). Medication-related osteonecrosis of the jaw: A survey of knowledge, practices and opinions of dentists. Annals of Medical Research, Cilt: 27 - Sayı: 9, 2421–2427. https://ajindex.com/articles/446229

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Migliorati CA, Woo SB, Hewson I, et al. A systematic review of bisphosphonate osteonecrosis (bon) in cancer. Support Care Cancer 2010;18:1099-106
  2. Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007;5:475-82
  3. Holtmann H, Lommen J, Kübler NR, et al. Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials. J Int Med Res 2018;46:4277-96
  4. Gutta R, Louis P. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:186-93
  5. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks and preventive strategies. J Oral Maxillofac Surg 2009;67:35-43
  6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7
  7. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. Aust Endod J 2009;35:119-30
  8. Ruggiero SL, Dodson TB, Fantasia J, et al. MedicationRelated Osteonecrosis of the Jaw–2014 Update. J Oral Maxillofac Surg 2014;72:1938-56
  9. Sahin O, Odabasi O, Aliyev T, et al. Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation. J Korean Assoc Oral Maxillofac Surg 2019;45:108-15
  10. Filleul O, Crompot E, Saussez S. Bisphosphonateinduced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010;136:1117-24
  11. Otto S, Tröltzsch M, Jambrovic V, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 2015;43:847- 54
  12. Yamazaki T, Yamori M, Ishizaki T, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012;41:1397- 403
  13. Alhussain A, Peel S, Dempster L, et al. Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosponates. J Oral Maxillofac Surg 2015;73:1095-105
  14. El-Rabbany M, Sgro A, Lam DK, et al. Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Am Dent Assoc 2017;148:584-94